Two-part Report Assessment Submission
You work in the Target Validation department of a pharmaceutical company. The CEO of your company has heard that GlaxoSmithKline is setting up a project to target the glycolytic pathway in cancer. Not wanting to be left behind, he has asked you to look into the pathway to identify any enzymes that would be suitable as the basis of an inhibitor discovery programme.
He has just finished reading the papers below, and so the differences between the desirability of a target and the druggability of a target are fresh in his mind. He has asked you to make sure you analyse both areas carefully when compiling your report, before drawing your conclusions.
The Challenge of Drugging Undruggable Targets in Cancer
Metabolic targets for cancer therapy, Nature Drug Discovery
Your 2-part report should include:
- Target Desirability analysis (Word '.doc' document with figures and references)
- History/background of target
- Involvement in disease
- Evidence of efficacy if target activity is modified
- Target Druggability analysis (Powerpoint '.ppt' file and Pymol '.pse' session)
The Word document should contain no more than 1500 words excluding references and figure legends.
The deadline for the Assessed Report is Monday 14th May 16:00 (BST) 2018